FEMALE SEXUAL DYSFUNCTION
Female sexual dysfunction affect up to 43% of women causing a "distress" or a psychological strain for the patients. A variety of chronic diseases in addition to menopause and different drugs represents the risk factors to a female sexual dysfunction. Since 2015 the FDA has approved Fliban...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Book |
| Published: |
IRBIS LLC,
2016-06-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_e04d76fcee654ab5ba9d70153d145a7b | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a C. DADAK |e author |
| 700 | 1 | 0 | |a M. BAYERLE-EDE |e author |
| 245 | 0 | 0 | |a FEMALE SEXUAL DYSFUNCTION |
| 260 | |b IRBIS LLC, |c 2016-06-01T00:00:00Z. | ||
| 500 | |a 2313-7347 | ||
| 500 | |a 2500-3194 | ||
| 500 | |a 10.17749/2070-4968.2015.9.4.086-088 | ||
| 520 | |a Female sexual dysfunction affect up to 43% of women causing a "distress" or a psychological strain for the patients. A variety of chronic diseases in addition to menopause and different drugs represents the risk factors to a female sexual dysfunction. Since 2015 the FDA has approved Flibanserin for the treatment of female libido although several other drugs have been proven efficacious. | ||
| 546 | |a RU | ||
| 690 | |a female sexual dysfunction | ||
| 690 | |a ogasms disorders | ||
| 690 | |a flibanserin | ||
| 690 | |a Gynecology and obstetrics | ||
| 690 | |a RG1-991 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Акушерство, гинекология и репродукция, Vol 9, Iss 4, Pp 86-88 (2016) | |
| 787 | 0 | |n https://www.gynecology.su/jour/article/view/185 | |
| 787 | 0 | |n https://doaj.org/toc/2313-7347 | |
| 787 | 0 | |n https://doaj.org/toc/2500-3194 | |
| 856 | 4 | 1 | |u https://doaj.org/article/e04d76fcee654ab5ba9d70153d145a7b |z Connect to this object online. |